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Abstract
Each year, many operations in the UK are performed with the patient awake, without the use of general anaesthesia. These
include joint replacement procedures, and in order to reduce patient anxiety, the supervising anaesthetist delivers the sedative
propofol intravenously using a target-controlled infusion (TCI) device. However, it is clinically challenging to judge the required
effect-site concentration of sedative for an individual patient, resulting in patient care issues related to over or under-sedation. To
improve the process, patient-maintained propofol sedation (PMPS), where the patient can request an increase in concentration
through a hand-held button, has been considered as an alternative. However, due to the proprietary nature of modern TCI pumps,
the majority of PMPS research has been conducted using prototypes in research studies. In this work, a PMPS system is presented
that effectively converts a standard infusion pump into a TCI device using a laptop with TCI software. Functionally, the system
delivers sedation analogous to a modern TCI pump, with the differences in propofol consumption and dosagewithin the tolerance
of clinically approved devices. Therefore, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved the
system as a safe alternative to anaesthetist-controlled TCI procedures. It represents a step forward in the consideration of PMPS as
a sedation method as viable alternative, allowing further assessment in clinical trials.
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Background
A considerable number of operations (over 800,000) per-
formed annually in the UK are conducted in the presence of
an anaesthetist, but without using general anaesthesia [1].
Lower limb surgical arthroplasty largely contributes to this
number, with the most common procedures being hip and
knee replacement (~200,000 such replacements were carried
out in 2016, excluding Scotland [2]). In such cases, regional
anaesthesia (numbing part of the body) using a spinal anaes-
thetic provides excellent operating conditions whilst reducing
some of the risks associated with general anaesthesia [3].
However, whilst a minority of patients are accepting of
experiencing surgery awake, a substantial number are not as
keen and can experience varying levels of anxiety either be-
fore or during the operation [4, 5]. As well as the obvious
negative impact on patient experience, procedural anxiety
can be associated with negative surgical outcomes including
post-operative pain [6]. To negate this issue, several tech-
niques have been tried and found to be effective at reducing
patient anxiety including visual distraction [7], patient educa-
tion [8] and music therapy [9].
In order to reduce patient anxiety during lower-limb
arthroplasty, anaesthetists commonly use intravenously deliv-
ered sedation. This is provided by the supervising anaesthetist,
with one option being administering propofol using computer-
assisted Target Controlled Infusion (TCI) [10]. Propofol is a
short-acting general anaesthetic and sedative agent with a rap-
id onset of action of approximately 30 s. It was first authorised
for clinical use in the UK in 1986 (FDA approval in 1989),
renewed in 2004 [11]. Whilst midazolam is perhaps more
commonly used, the advantages of propofol by TCI include
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more rapid patient wake-up, less post-procedural confusion
and delirium, and the ability to easily convert to general an-
aesthesia if required [12]. In such a system, a target-controlled
infusion device delivers an infusion rate of propofol that varies
over time to achieve a specified plasma or effect-site (i.e.
brain) drug concentration (Fig. 1).
However, risks do exist regarding customisable drug ad-
ministration such as TCI. These include the incorrect input of
patient demographics resulting in inaccurate drug dosing, or
the incorrect selection of TCI model for the drug to be infused
i.e. placing a syringe containing a different drug into a device
programmed for propofol delivery, or vice versa [13].
Additionally, the required effect-site concentration for an in-
dividual patient can be difficult to determine, as anaesthetists
can often misjudge the patients’ anxiety levels [14]. This
could result in either patients feeling under-sedated, causing
the patient to be unnecessarily anxious, or over-sedated; both
of which can promote adverse physiological states [15].
In order to improve the sedation process, patient-maintained
propofol sedation (PMPS) is an alternative mechanism to anaes-
thetist control.ATCI system is againutilised, but insteadofbeing
anaesthetist controlled, the effect-site concentration of sedation is
manipulated by the patient using a handheld button. The use of
PMPSor patient-controlled sedationhas previously been investi-
gated in a number of small case series, including dental [16],
endoscopy [17] and outpatient surgical [18], showing positive
results regarding sedation concentration, patient anxiety levels
and recovery time. Our group has previously conducted a pilot
study of this sedative technique [19]. However, to date there has
been only a small number of randomised controlled trials of
PMPS in a clinical setting [20–22], of which none have used
modernpropofolTCIpumpswith thepharmacokineticalgorithm
‘built in’ as an option (i.e. Schnider effect-site modelling [10]) in
comparing PMPS against the anaesthetist-controlled standard.
This is, in part, because modern TCI infusions devices
(such as the B. Braun Space shown in Fig. 1) are normally
locked down and proprietary in design, meaning there is little
or no flexibility in terms of integrating with or amending soft-
ware protocols and interfaces [23]. Due to this, and the fact
that commercially produced TCI pumps do not incorporate a
patient-triggered interface, PMPS research studies have used
specifically developed prototypes. These include the use of an
infusion device connected to a computer running research
software [20, 22], or an infusion device incorporated with a
TCI microprocessor and patient interface [21]. Whilst existing
studies have reported the impact of PMPS in terms of clinical
and patient outcomes, there has been very little technical ex-
planation regarding the development, integration, testing and
deployment of TCI enabled PMPS systems.
In this work, a PMPS system utilising a B. Braun Perfusor®
fm infusion device [24] connected to a laptop running bespoke
TCI software and interfacing with a patient-controlled button
device is presented. The system allows a direct comparison for
surgical procedures between PMPS and anaesthetist-controlled
propofol sedation (ACPS), the key goal of the associated
National Institute for Health Research (NIHR) project [25] for
which it was designed. Firstly the system architecture is de-
scribed, including the hardware, software and communication
methods employed. Additionally, the design and development
of the system interface is considered, in order to ensure patient
safety and reduce risk; a prerequisite for gaining Medicines and
Healthcare Products Regulatory Agency (MHRA) approval for
clinical trial deployment in the UK [26]. Finally, the perfor-
mance of the proposed PMPS system is compared to a modern
TCI integrated infusion pump, in terms of propofol dosage and
total consumption for different patient demographics and target
effect-site levels.
Methods
In this section the layout of the PMPS system, its hardware,
and communication devices are described. The software de-
veloped in order to drive the sedation pump, incorporating the
Schnider TCI algorithm to maintain a given effect-site seda-
tion level is also presented. Finally the system interface design
and its testing is considered, including key usability and safety
functionality in order to gain MHRA approval for clinical use.
PMPS system layout
The layout of the PMPS system, including its hardware and
communication methods is set out in Fig. 2. A laptop is con-
nected to a B. Braun Perfusor® fm infusion device via a stan-
dard RS-232 serial port allowing two-way data transfer. The
laptop contains software that implements the TCI algorithm,
in order to calculate the required infusion rate for the target
effect-site propofol concentration. It is modified to accept pa-
tient demand for an increase in sedation, via a USB connected
button. In response to the laptop’s software-generated instruc-
tions, the pump delivers the appropriate infusion rate, with
infusion data saved on the laptop in comma-separated values
(csv) format, for data analysis.Fig. 1 B.Braun Perfusor® Space Target Controlled Infusion Device
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PMPS software design
The PMPS system’s software controls the sedation process, by
responding to patient requests for increased sedation, calculat-
ing the required infusion rate in order to achieve it, and mon-
itoring if it is safe to command the infusion pump to respond
as appropriate. The software has been built as a standard
Microsoft Windows application, ensuring it is intuitive to
use for the supervising anaesthetist. In order to calculate the
required infusion rate of propofol for a given concentration,
current TCI systems are pre-programmed with either the
Marsh [27] or Schnider [10] pharmacokinetic models.
Whilst the two models differ in terms of how they calculate
initial bolus and maintenance infusion rates, the Schnider
model is preferred over the Marsh model for effect-site con-
centration targeting [28]. As such, it is the Schnider model that
has been incorporated into the PMPS software, based on the
mathematical equations and code of STANPUMP [29]. Fully
open-source, STANPUMP is a computer program for driving
an infusion pump, freely available to investigators and
anaesthetists for research and clinical purposes.
The Schnider pharmacokinetic model requires patient
weight, age, height, and lean body mass (LBM) (calculated
from weight, gender and height) in order to calculate the in-
fusion rate for a given effect-site concentration. Therefore, the
first action the PMPS software undertakes is to request patient
information to be inputted by the supervising anaesthetist.
Once completed, and the anaesthetist and patient chose to
begin sedation, the software starts sedation at an infusion rate
in order to achieve a baseline effect-site concentration (Ce) of
0.5 μg/ml. A flowchart of how the PMPS software reacts to
patient requests for increased sedation, the processes initiated
and the decisions considered is shown in Fig. 3.
After initial setup and sedation commencement at a target
Ce of 0.5 μg/ml, the PMPS software is then ready to respond
Fig. 2 PMPS system layout and components
Fig. 3 PMPS software flowchart showing response to patient request for
sedation increase
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to input from the patient button. When pressed by the patient
(a single click), the software checks two conditions to ensure it
is safe to increase the sedation level. Firstly, when the sedation
starts, and every time sedation is increased through a patient
button press, a lockout time of 2 min starts to count down.
Within this lockout time, any button press requesting an in-
crease in Ce is denied, to make sure the sedation level cannot
be increased too quickly. Secondly, the software checks if the
maximum Ce level has been reached. For the purpose of this
project this has been set at 2.0 μg/ml, and if reached, again the
PMPS software denies the request for an increase in Ce.
If both conditions are met to allow a sedation increase, the
software uses the Schnider model to calculate the required
infusion rate to maintain an increase of 0.2 μg/ml in target
Ce level (e.g. 0.5 to 0.7 μg/ml, as extensively studied and
deemed appropriate in previous research [30]). This data is
then outputted to the B. Braun Perfusor® fm infusion pump
through the serial port, and the pump responds accordingly. If
the patient does not press the button to request an increase in
sedation for 15 min, the target Ce level decrements by
0.1 μg/ml. This is to balance the need to maintain a satisfac-
tory sedation level, avoiding the unpleasant sensation for a
patient of going to sleep, then waking up, then going to sleep;
with minimising their drug exposure over the course of the
surgery to increase the speed of patient wake-up time after the
operation is complete [31].
PMPS anaesthetist interface
The PMPS system allows two-way communication between
the software and the infusion pump, allowing data to be taken
from the pump and displayed to the supervising anaesthetist
through an interface on the system laptop (Fig. 2). The advan-
tage of such an approach is that key sedation information can
be presented on a single screen, without the need to navigate a
number of sub-menus as with current commercially produced
pump displays, therefore reducing the mental effort required
for operation [32]. Additionally, information distinct to the
PMPS process is also displayed. The PMPS anaesthetist inter-
face shown in Fig. 4 has been developed in conjunction with
Fig. 4 PMPS anaesthetist interface with the following displays: (a) –
Button control display showing successful and denied patient request
for increased sedation; (b) – Sedation metrics display showing sedation
information; (c) – Anaesthetist override button allowing the anaesthetist
to take system control; (d) – Sedation pause button allowing the anaes-
thetist to pause sedation
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practising anaesthetists [33], to ensure that the most relevant
sedation information and functionality is displayed and in-
cluded to ensure patient safety.
The PMPS interface consists of several sections that dis-
play different information pertinent to the patient-maintained
sedation process. The button control display (see (a) in Fig. 4)
informs the supervising anaesthetist of the number of sedation
increase requests made by the patient, both successful and
failed, and the ratio between the two so that the anxiety level
Table 1 Patient metrics for the PMPS system test sedation simulations
Patient
ID
Gender Age
(years)
Height
(cm)
Weight
(kg)
Lean
Body
Mass (kg)
A Male 71 166 85 59.94
B Female 68 161 65 45.43
Fig. 5 Propofol consumed (a),
dosage – loading dose over 1st
minute and target maintenance for
remainder of sedation period (b)
and target effect-site concentra-
tion (c) during the sedation pro-
cess for simulation A
J Med Syst          (2019) 43:247 Page 5 of 8   247 
of the patient can be broadly deduced. The sedation metrics
display ((b) in Fig. 4) displays all of the key sedation metrics
on screen simultaneously. An anaesthetist override button ((c)
in Fig. 4) has been included on the PMPS interface to allow
the anaesthetist to take complete control in the advent of a
medical issue. On selecting this function, the patient button
is de-activated, and the anaesthetist can raise and lower the
target effect-site propofol concentration as they see fit. Finally,
the sedation pause button ((d) in Fig. 4) allows the supervising
anaesthetist to temporarily pause the sedation process (i.e. set
the infusion rate to zero). This is so syringe changes or patient
transfer from the anaesthesia room to the operating theatre can
take place, and when completed the sedation will restart at the
target effect-site concentration previously set before the pause.
Results
In order to ensure the PMPS system delivers sedation correct-
ly as per the Schnider TCI algorithm, the performance of the
Fig. 6 Propofol consumed (a),
dosage – loading dose over 1st
minute and target maintenance for
remainder of sedation period (b)
and target effect-site concentra-
tion (c) during the sedation pro-
cess for simulation B
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system has been compared to that of a commercially produced
TCI pump (the B. Braun Perfusor® Space shown in Fig. 1).
This has been done in terms of the amount of propofol con-
sumed and the dosage rate during the sedation process for a
number of patient metrics at differing target effect-site con-
centrations. In order to ensure the patient metrics and sedation
levels are representative of primary lower-limb arthroplasty
operations, the following simulations replicate sedation pro-
cedures that have taken place at the Nottingham University
Hospitals NHS Trust. Table 1 shows the metrics of the patients
used for the two sedation simulations. The lean body mass
were calculated using the James formula [34], which is used
for Schnider model TCI calculations [28].
The following graphs shown in Figs. 5 and 6 show the
sedation metrics (propofol consumed, propofol dosage and
target effect-site concentration) for simulations A and B re-
spectively. The propofol consumed is measured in milligrams
(mg), whilst dosage is the simulated amount of propofol that
would be consumed by the simulated patient per hour, nor-
malised by their actual body weight (mg/kg/h).
During simulation A, the target Ce started at the base level
of 0.5 μg/ml, increasing to 0.8 μg/ml through two button
presses up to 36 min, with one decrement occurring at around
the 20 min mark. No more increases were requested by the
patient, with the target Ce decrementing twice to 0.6 μg/ml
until the end of the operation 12 min later. As can be seen for
both the amount of propofol consumed and the dosage, the
profile for the PMPS system and the Perfusor® Space TCI
pump is near identical. At the end of the sedation period the
total amount of propofol consumed was 140.49 versus
140.91 mg for the PMPS system and the TCI pump respec-
tively (a difference of 0.3%), whilst the final propofol dosage
was 1.38 mg/kg/h for both.
Simulation B represents a calmer patient, who did not re-
quest an increase in sedation throughout the surgery. The tar-
get Ce started at the base level of 0.5 μg/ml, and remained at
that level with no increase requests or decrements (as the tar-
get Ce was already at the lowest level) until the end of the
operation. Again the profile of propofol consumed and dosage
is near identical for both systems. At the end of the sedation
period the total amount of propofol consumed was 77.77 ver-
sus 78.40 mg for the PMPS system and TCI pump respective-
ly (a difference of 0.8%), whilst the final propofol dosage was
1.39 versus 1.41 mg/kg/h (a difference of 1.2%).
Discussion
A PMPS system was created using a laptop running TCI soft-
ware controlling a standard infusion pump to run as a modern
TCI pump. This overcame the proprietary, locked-down de-
signs of modern TCI pumps, and allowed the addition of a
patient interface, allowing the comparison of PMPS and
ACPS. The PMPS system delivers propofol sedation in a
way analogous to a commercially available TCI pump when
running simulated primary lower-limb arthroplasty proce-
dures. In the simulations made over different patient metrics
and target effect-site concentration profiles, the largest differ-
ence between the PMPS system and the Perfusor® Space TCI
pump was 0.6 mg in terms of propofol consumed and
0.02 mg/kg/h in terms of dosage; a smaller variation than the
tolerance of the commercial device [35]. Additionally, the
inclusion of a laptop allowed an interface to be developed that
includes all the data required by the supervising anaesthetist
on a single display, reducing mental load and fatigue.
The PMPS system presented performed equivalently to a
commercially produced TCI device in simulated sedation for
lower-limb arthroplasty operations. The system will therefore
allow comparison of PMPS and ACPS techniques in a medi-
cally approved, clinical trial setting.
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